Monogram Technologies :: Transforming Orthopedic Surgery Through Precision Automation, Advanced Imaging & Patient-Specific Solutions

Monogram Technologies is an AI-driven robotics company focused on transforming orthopedic surgery through precision automation, advanced imaging, and patient-specific solutions. Headquartered in Austin, Texas, and trading on NASDAQ under the ticker MGRM, Monogram Technologies develops integrated systems that combine robotics with custom 3D-printed implants to address limitations of traditional one-size-fits-all joint replacement procedures.

The company’s primary robot-based offering is the mBôs™ TKA System, a navigated robotic platform cleared by the FDA in 2025 for total knee arthroplasty. This semi-autonomous system is engineered to deliver accurate, repeatable bone cuts that enable better-fitting implants and more stable joint reconstructions. The robotic arm provides 7 degrees of freedom, allowing surgeons to reach optimal resection angles while maintaining tight control boundaries that protect surrounding soft tissues.

Unique operational features include foot-actuated controls, which free the surgeon’s hands for additional instruments or safety monitoring during the procedure. Continuous navigation tracks both the patient’s anatomy and the robot in real time, while the system is designed to execute optimized cut paths autonomously once the plan is confirmed. Monogram Technologies emphasizes conservative tissue preservation and repeatability to reduce intraoperative variability.

Supporting software uses machine learning to automate the majority of preoperative case planning from CT scans. This dramatically shortens processing time and allows clinical users to incorporate personal preferences quickly. The intuitive user interface includes automated registration, patient-specific alignment suggestions, and post-case reporting. A planned next-generation navigation technology called mVision is under development for future integration to further improve tracking accuracy.

Monogram Technologies pairs its robotic system with plans for personalized 3D-printed implants (branded mPress) that match individual bone morphology. By milling precise cavities with the robot and inserting custom-fit components, the approach aims for improved stability, bone preservation, and long-term outcomes compared with standard off-the-shelf implants. The platform is built with scalability in mind, with potential future expansion beyond knee surgery.

Monogram Technologies positions its technology in a growing market, noting projections that robotic-assisted knee replacements could reach 50% of procedures by 2027. The system focuses on speed (fast registration and cutting), safety, workflow efficiency, and reduced surgical time, which can lower infection risk. Early milestones include cadaver labs, clinical studies, and regulatory progress.

Leadership at Monogram Technologies includes founder and Chief Medical Officer Dr. Douglas Unis along with executives with deep experience in orthopedics and technology scaling. In 2025, Monogram Technologies entered a new phase when it became part of Zimmer Biomet, integrating its mBôs platform alongside existing robotics solutions.

Overall, Monogram Technologies aims to shift orthopedic care toward truly personalized, robotically executed procedures that combine mechanical precision with digital intelligence.